Alexo Therapeutics, a clinical-stage immuno-oncology company developing therapies to block the CD47 myeloid checkpoint mechanism, today announced the change of the Company’s name to ALX Oncology. The new name and logo will differentiate ALX Oncology (ALX) from other companies in the field as the Company advances its clinical programs.
“Our new name further identifies us as an oncology drug developer and distinguishes us from other companies in this sector,” said Jaume Pons, Ph.D., ALX Oncology’s President and Chief Executive Officer.
ALX Oncology is developing ALX148, a high affinity CD47 blocker currently in clinical development (NCT03013218). Preliminary results from the Phase 1 trial were recently presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. “Our study results show that ALX148 is generally well tolerated as a single agent and in combination with pembrolizumab, trastuzumab, or rituximab in patients with advanced solid tumors and non-Hodgkin lymphoma,“ said Sophia Randolph, M.D., Ph.D., ALX Oncology’s Chief Medical Officer. “We look forward to reporting the results of ALX148 combinations in expanded patient populations at upcoming conferences.”